Kinetics of the hepatitis B core-related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide

被引：0

作者：

Itokawa, Norio ^{[1
]}

Atsukawa, Masanori ^{[1
,20
]}

Tsubota, Akihito ^{[2
]}

Ishikawa, Toru ^{[3
]}

Toyoda, Hidenori ^{[4
]}

Takaguchi, Koichi ^{[5
]}

Watanabe, Tsunamasa ^{[6
]}

Ogawa, Chikara ^{[7
]}

Hiraoka, Atsushi ^{[8
]}

Okubo, Hironao ^{[9
]}

Uojima, Haruki ^{[10
]}

Chuma, Makoto ^{[11
]}

Nozaki, Akito ^{[11
]}

Kato, Keizo ^{[12
]}

Mikami, Shigeru ^{[13
]}

Tani, Joji ^{[14
]}

Morishita, Asahiro ^{[14
]}

Tada, Toshifumi ^{[15
]}

Asano, Toru ^{[16
]}

Senoh, Tomonori ^{[5
]}

Oikawa, Tsunekazu ^{[17
]}

Okubo, Tomomi ^{[18
]}

Kumada, Takashi ^{[19
]}

Iwakiri, Katsuhiko ^{[1
]}

机构：

[1] Nippon Med Sch, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo, Japan

[2] Jikei Univ, Project Res Units PRU, Sch Med, Res Ctr Med Sci, Tokyo, Japan

[3] Saiseikai Niigata Hosp, Dept Hepatol, Niigata, Japan

[4] Ogaki Municipal Hosp, Dept Gastroenterol, Ogaki, Japan

[5] Kagawa Prefectural Cent Hosp, Dept Hepatol, Takamatsu, Japan

[6] St Marianna Univ, Sch Med, Dept Internal Med, Kawasaki, Kanagawa, Japan

[7] Takamatsu Red Cross Hosp, Dept Gastroenterol & Hepatol, Takamatsu, Japan

[8] Ehime Prefectural Cent Hosp, Gastroenterol Ctr, Matsuyama, Japan

[9] Juntendo Univ, Nerima Hosp, Dept Gastroenterol, Tokyo, Japan

[10] Kitasato Univ, Sch Med, Dept Gastroenterol, Sagamihara, Kanagawa, Japan

[11] Yokohama City Univ, Med Ctr, Gastroenterol Ctr, Yokohama, Japan

[12] Shinmatusdo Cent Gen Hosp, Div Gastroenterol & Hepatol, Matsudo, Japan

[13] Kikkoman Gen Hosp, Dept Internal Med, Div Gastroenterol, Noda, Japan

[14] Kagawa Univ, Dept Gastroenterol, Grad Sch Med, Kagawa, Japan

[15] Japanese Red Cross Himeji Hosp, Dept Internal Med, Hyogo, Japan

[16] Tokyo Metropolitan Bokutoh Hosp, Dept Internal Med, Tokyo, Japan

[17] Jikei Univ, Dept Gastroenterol & Hepatol, Sch Med, Tokyo, Japan

[18] Chiba Hokusoh Hosp, Nippon Med Sch, Dept Internal Med, Div Gastroenterol, Inzai, Chiba, Japan

[19] Gifu Kyoritsu Univ, Dept Nursing, Ogaki, Japan

[20] Nippon Med Sch, Div Gastroenterol & Hepatol, 1-1-5 Sendagi,Bunkyo Ku, Tokyo 1138603, Japan

来源：

HEPATOLOGY RESEARCH | 2024年 / 54卷 / 11期

关键词：

hepatitis B core-related antigen; hepatitis B surface antigen; tenofovir alafenamide; HEPATOCELLULAR-CARCINOMA; ENZYME-IMMUNOASSAY; NEGATIVE PATIENTS; SURFACE-ANTIGEN; RISK; DNA; MONOTHERAPY; EFFICACY; THERAPY; FAILURE;

D O I：

10.1111/hepr.14052

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

AimAn association between hepatitis B core-related antigen (HBcrAg) kinetics and hepatocarcinogenesis during nucleoside (t)id analog (NA) treatment has recently been reported. HBcrAg kinetics and factors associated with HBcrAg response during tenofovir alafenamide (TAF) administration remain unclear. In this multicenter retrospective study, we aimed to clarify the efficacy and safety of TAF in treatment-na & iuml;ve patients with chronic hepatitis B, focusing on the reduction in HBcrAg levels.MethodsPatients were treated with TAF monotherapy for 96 weeks, and the kinetics of HBcrAg during treatment and the factors associated with HBcrAg response (defined as a change in HBcrAg of -1 log IU/mL from baseline) were evaluated.ResultsThe study population comprised 241 patients, 36.9% of whom were HBeAg-positive. The median baseline HBcrAg level was 4.7 log IU/mL. The median change in HBcrAg from baseline was -1.1 log IU/mL at 96 weeks after treatment. The HBcrAg response rate at 96 weeks was 56.6% (43/76). Multivariate analysis revealed high alanine transaminase level as an independent baseline factor associated with HBcrAg response at 96 weeks of treatment (p = 4.53 x 10-6). No correlation was found between the HBcrAg and hepatitis B surface antigen kinetics in patients treated with TAF monotherapy.ConclusionsIn TAF monotherapy for patients with chronic hepatitis B, HBcrAg levels were significantly decreased and baseline alanine transaminase level is an important factor associated with HBcrAg reduction. As no correlation was found between HBcrAg and reduced hepatitis B surface antigen levels in this study, HBcrAg kinetics in addition to hepatitis B surface antigen may need to be monitored during TAF treatment. In tenofovir alafenamide monotherapy for chronic hepatitis B patients, hepatitis B core-related antigen (HBcrAg) levels were significantly decreased, and baseline alanine transaminase level was an important factor associated with HBcrAg reduction. As no correlation was found between HBcrAg and reduced hepatitis B surface antigen levels, HBcrAg kinetics in addition to hepatitis B surface antigen may need to be monitored during tenofovir alafenamide treatment. image

引用

页码：993 / 1003

页数：11

共 34 条

[1]

[Anonymous], 2008, HEPATITIS B

[2] Hepatitis B core-related antigen levels predict recurrence-free survival in patients with HBV-associated early-stage hepatocellular carcinoma: results from a Dutch long-term follow-up study [J].

Beudeker, Boris J. B. ;

Groothuismink, Zwier M. A. ;

de Man, Robert A. ;

Witjes, Caroline D. M. ;

van Der Eijk, Annemiek A. ;

Boonstra, Andre ;

Sonneveld, Milan J. .

JOURNAL OF VIRAL HEPATITIS, 2021, 28 (01) :205-208

[3]

Buti M., 2016, LANCET GASTROENTEROL, V3, p196 206

[4] Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial [J].

Chan, Henry L. Y. ;

Fung, Scott ;

Seto, Wai Kay ;

Chuang, Wan-Long ;

Chen, Chi-Yi ;

Kim, Hyungjoon ;

Hui, Aric Josun ;

Janssen, Harry L. A. ;

Chowdhury, Abhijit ;

Tsang, Tak Yin Owen ;

Mehta, Rajiv ;

Gane, Edward ;

Flaherty, John F. ;

Massetto, Benedetta ;

Gaggar, Anuj ;

Kitrinos, Kathryn M. ;

Lin, Lanjia ;

Subramanian, G. Mani ;

McHutchison, John G. ;

Lim, Young-Suk ;

Acharya, Subrat K. ;

Agarwal, Kosh .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2016, 1 (03) :185-195

[5] Hepatocellular carcinoma and hepatitis B virus [J].

Chan, HLY ;

Sung, JJY .

SEMINARS IN LIVER DISEASE, 2006, 26 (02) :153-161

[6] Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].

Chen, CJ ;

Yang, HI ;

Su, J ;

Jen, CL ;

You, SL ;

Lu, SN ;

Huang, GT ;

Iloeje, UH .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73

[7] Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy [J].

Cheung, K. -S. ;

Seto, W. -K. ;

Wong, D. K. -H. ;

Lai, C. -L. ;

Yuen, M. -F. .

JOURNAL OF VIRAL HEPATITIS, 2017, 24 (08) :654-661

[8] Drug therapy - Hepatitis B virus infection [J].

Dienstag, Jules L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (14) :1486-1500

[9] Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B [J].

Gish, R. G. ;

Chang, T. -T. ;

Lai, C. -L. ;

de Man, R. ;

Gadano, A. ;

Poordad, F. ;

Yang, J. ;

Brett-Smith, H. ;

Tamez, R. .

JOURNAL OF VIRAL HEPATITIS, 2010, 17 (01) :16-22

[10] The Molecular Virology of Hepatitis B Virus [J].

Glebe, Dieter ;

Bremer, Corinna M. .

SEMINARS IN LIVER DISEASE, 2013, 33 (02) :103-112

← 1 2 3 4 →